Stomach (Gastric) cancer trials

AI-generated summary

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer is being studied. Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer +4 • Eligibility: * INCLUSION CRITERIA: * Participants with an appropriate HLA match for available Surgery Branch KRAS TCRs with evaluable metastatic solid cancer (e.g., gastrointestinal, genitourinary, breast, ovarian, non-small cell…. Goal: Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases". is being studied. Conditions: Chronic Liver Disease and Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease +4 • Eligibility: Inclusion Criteria: 1. Patients * diagnosed with chronic liver disease (viral or not) * diagnosed with at least one liver nodule for which a biopsy is planned as…. Goal: Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut National de la Santé Et de la Recherche Médicale, France.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors is being studied. Conditions: Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult +25 • Eligibility: Inclusion Criteria: \- Must have a pathologically confirmed advanced and unresectable or metastatic solid tumor listed below with documented disease progression on last standard treatment. Part 1 only:…. Goal: The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D). Phase/Status/Sponsor: Unknown phase; RECRUITING; NiKang Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. is being studied. Conditions: Metastatic Solid Tumors, Stage 4 Cancer • Eligibility: Inclusion Criteria: 1. Life expectancy of at least 90 days. 2. Histologically confirmed advanced metastatic solid tumors located between the thoracic inlet and the pelvic floor, that have…. Goal: This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Phase/Status/Sponsor: Unknown phase; RECRUITING; New Phase Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors is being studied. Conditions: Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland +7 • Eligibility: Inclusion Criteria: This study will look at solid tumors (as a basket trial for any solid cancer) with HER2 positivity based on IHC Procurement Inclusion Criteria 1. The…. Goal: This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cells called HER2 chimeric antigen receptor specific cytotoxic T lymphocytes (HER2 specific CAR T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system including HER2 specific CAR T cell react to the tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma is being studied. Conditions: Mesothelioma, Thymoma, Pancreatic Neoplasms +2 • Eligibility: * INCLUSION CRITERIA: * All participants greater than or equal to 2 years of age with malignant mesothelioma. * All participants greater than or equal to18 years of…. Goal: Background: * Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. * Mesothelioma accounts for 0.10% of deaths annually in the United States. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The ZANGEA trial tests zanidatamab together with pembrolizumab and chemotherapy in adults with metastatic gastroesophageal adenocarcinoma that is HER2-positive and PD-L1-positive, and who have not had palliative treatment before. - It is an open-label, single-arm phase II study enrolling about 80 patients at roughly 30 sites in Germany and Austria to assess efficacy, safety, tolerability, and quality of life. - The study also includes exploratory aims to compare results with a historical regimen and to identify molecular biomarkers that predict response or toxicity. - Key exclusions include untreated CNS metastases, active autoimmune disease, prior anti-HER2 therapy for GEA, certain infections, and pregnancy or breastfeeding.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests nanvuranlat in adults with biliary tract cancer to find a recommended dose regimen (Part A) and to study its effect on overall survival compared with the physician’s best choice (Part B). Participants are 18 years or older with advanced, metastatic, or unresectable BTC who have received one prior platinum-based therapy. Treatments are given every two weeks with safety checks, tumor imaging, and exploratory tests to understand how the drug works. Key exclusions include active CNS metastases, significant cardiovascular disease, HIV not on therapy, active HBV or HCV infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests precision-based immunotherapy approaches for primary liver cancer (hepatocellular carcinoma and cholangiocarcinoma) and aims to build a biospecimen repository to study the biology of the cancer and how patients respond to treatment. - It will enroll adults 18 and older with liver cancer who are receiving or planning to receive immunotherapy, and will collect medical records, imaging, tumor tissue, and samples such as blood, urine, and stool over time. - Researchers will perform a wide range of analyses (genomics, epigenetics, metabolomics, microbiome, and immune monitoring) to identify factors that predict response or resistance to immunotherapy and to understand disease progression. - HIV infection is an exclusion criterion, and the study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests whether adding durvalumab to the chemotherapy drugs gemcitabine and cisplatin given before surgery helps treat high-risk, resectable intrahepatic cholangiocarcinoma (liver cancer). - It is for adults who are considered candidates for curative surgery. - Researchers want to learn how many patients can complete the pre-surgery therapy and then have the tumor completely removed, as well as rates of major tumor response and overall survival after treatment. - Key exclusions include pregnancy, active autoimmune diseases, active infections (including hepatitis B or C), recent major surgery or current immunosuppressive therapy, and other conditions that could affect safety or results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biobank for Cholestatic Liver Diseases. is being studied. Conditions: Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma +1 • Eligibility: Inclusion Criteria: PSC * Patients diagnosed with PSC and who are between the age of 18 and 85 at time of enrollment in the study. * The diagnosis…. Goal: This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis (PSC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a phase I dose-escalation trial testing AU409, an RNA transcription modulator, to find the safest and recommended dose and to study its safety in adults with advanced liver cancers or solid tumors that have spread to the liver. Eligible participants are adults 18 and older with an advanced solid tumor that has exhausted standard treatments (or no good options), especially with liver-dominant disease or primary liver cancer; exclusions include untreated brain metastases, serious heart problems, active hepatitis B, pregnancy, or recent anticancer therapy. The study aims to determine the maximum tolerated dose and the recommended phase II dose and to assess safety and how AU409 behaves in the body. It will also look for early signs of anti-tumor activity on imaging and may collect tumor tissue and blood samples for analysis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests BOLD-100 given with the chemotherapy FOLFOX in adults with advanced gastrointestinal cancers (such as colorectal, pancreatic, gastric cancers, and cholangiocarcinoma) to assess safety and tolerability, using a dose-escalation phase followed by expansion. - In the colorectal cancer arm (Arm VII), eligible patients who are oxaliplatin-naïve and have had only one prior metastatic therapy will be randomized to three groups: BOLD-100 at 500 mg/m2 with FOLFOX, BOLD-100 at 625 mg/m2 with FOLFOX, or FOLFOX alone, with quality-of-life assessments. - The trial aims to learn whether adding BOLD-100 provides anti-tumor activity and how it affects patients’ quality of life, while establishing safe dose levels. - Key exclusions include neuropathy greater than grade 2, CNS metastases, active HIV on ART, DPD deficiency, prior exposure to BOLD-100 (for Arm VII), MSI-H tumors, and recent major treatments or other serious conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors is being studied. Conditions: Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer +1 • Eligibility: 1. Willing to sign the informed consent form and follow the requirements specified in the protocol. 2. Life expectancy ≥ 3 months. 3. Tumor specimen available for CDH17…. Goal: This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; ArriVent BioPharma, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer is being studied. Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * Participant is considered an adult according to local regulation at the time of signing the informed consent form (ICF). * Female participant is not pregnant,…. Goal: Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Astellas Pharma Global Development, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial compares rilvegostomig plus gemcitabine and cisplatin versus durvalumab plus gemcitabine and cisplatin as first-line treatment for advanced biliary tract cancer. - It is for adults with unresectable locally advanced or metastatic BTC, including intrahepatic or extra-hepatic cholangiocarcinoma and gallbladder cancer, who have not yet received systemic therapy for advanced disease and have measurable disease with good performance status. - The study aims to learn which regimen provides better efficacy and acceptable safety when used at the start of treatment. - Key exclusions include ampullary cancer, prior systemic therapy for unresectable or metastatic BTC, prior exposure to immune-targeting therapies, active autoimmune disease requiring steroids, and certain interstitial lung disease or serious skin conditions. - Sponsor: AstraZeneca; Status: Recruiting; Phase: Unknown.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies is being studied. Conditions: Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma +1 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years 2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 3. Histologically confirmed diagnosis of any of the following: • Gastric or…. Goal: The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anwaar Saeed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer is being studied. Conditions: Biliary Tract Cancer • Eligibility: Inclusion Criteria 1. Histologically- or cytologically-confirmed Biliary Tract Cancer (BTC), including Gallbladder Cancer (GBC), Intrahepatic Cholangiocarcinoma (ICC), or Extrahepatic Cholangiocarcinoma (ECC). 2. Locally advanced unresectable or metastatic BTC…. Goal: The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jazz Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Institutional Registry of Rare Diseases is being studied. Conditions: Rare Diseases, Amyloidosis, Sarcoidosis +23 • Eligibility: Inclusion Criteria: * Clinical and/or molecular diagnosis of any of the following rare diseases: Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn…. Goal: The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD). Moreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Hospital Italiano de Buenos Aires.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis is being studied. Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult +18 • Eligibility: Inclusion Criteria: * Patient must be ≥ 18yrs of age. * Patient must have the ability to understand, and the willingness to sign, a written informed consent form.…. Goal: This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b. Phase/Status/Sponsor: Unknown phase; RECRUITING; Neonc Technologies, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests Gallium-68 FAPI PET/CT to see if it improves detection, staging, and restaging of biliary tract cancers compared with the standard FDG PET/CT. It is for adults 18 and older with suspected or confirmed biliary cancers, including gallbladder cancer, cholangiocarcinoma, or suspected recurrence after treatment. The study will assess how well FAPI detects primary tumors, lymph node involvement, and metastases and whether it changes clinical decisions or reduces the need for invasive procedures. Participants must give informed consent, and those with a concurrent malignancy are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers is being studied. Conditions: Cancer • Eligibility: Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\] 2. Age 18 years or older, is willing and able to provide…. Goal: TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tizona Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Target-specific immunoPET Imaging of Digestive System Carcinoma is being studied. Conditions: Malignancy, Digestive Cancer, Digestive System Neoplasm +12 • Eligibility: Inclusion Criteria: 1. Aged 18-75 years old and of either sex； 2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging; 3.…. Goal: The aim of this study is to establish and optimize the target-specific PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated. Phase/Status/Sponsor: Unknown phase; RECRUITING; RenJi Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Collection of Blood From Patients With Cancer is being studied. Conditions: Prostate Cancer, Breast Cancer, Colon Cancer +2 • Eligibility: * INCLUSION CRITERIA: Patients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible. Performance status of ECOG 0, 1, 2,…. Goal: This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests the drug tivozanib for biliary tract cancers (cholangiocarcinoma and gallbladder cancer) in adults who have already had chemotherapy, to find the safest and most effective dose and to learn its overall response rate. It is open-label, non-randomized, and carried out at a single center, using 28-day treatment cycles (3 weeks on, 1 week off) with efficacy checked every 8 weeks. Eligible participants are adults 18 or older with biliary tract cancer not removable by surgery who have had prior first-line chemotherapy and have adequate organ function. Key exclusions include prior tivozanib use, pregnancy, and significant cardiovascular disease or uncontrolled hypertension.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers is being studied. Conditions: Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer +1 • Eligibility: Inclusion Criteria: 1. Patients must have signed a written informed consent form prior to any trial specific procedures; 2. Patients must be ≥18 years old; 3. Histologically confirmed…. Goal: International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different tumor types. Phase/Status/Sponsor: Unknown phase; RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers is being studied. Conditions: Head and Neck Tumors, Kidney Cancers, Small Cell Lung Cancers +3 • Eligibility: * INCLUSION CRITERIA: * Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma/paraganglioma (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), or Head \& Neck…. Goal: Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests adding lenvatinib to nivolumab plus chemotherapy for gastric cancer with peritoneal metastasis and malignant ascites. - It is for adults with newly diagnosed or recurrent/metastatic gastric or GEJ adenocarcinoma who have peritoneal metastasis with grade ≥2 ascites and a PD-L1 CPS ≥5. - The study aims to learn about the safety and efficacy of this combination and whether it can improve outcomes, such as survival, in this group. - Key exclusions include uncontrolled illness or infection, pregnancy or breastfeeding, HIV or active hepatitis B/C infection, recent major surgery, and other concurrent cancer therapies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This open, multicenter trial tests SHR-A1811 combined with chemotherapy and/or immunotherapy in adults with HER2-positive advanced or metastatic gastric or gastroesophageal junction cancer. It has two parts: Phase Ib to assess safety, tolerability, how the drug behaves in the body, immune response, and early anti-tumor signals; Phase II to assess how well the combination works and its safety. Eligible participants are adults aged 18 to 75 with unresectable or metastatic HER2-positive gastric/GEJ adenocarcinoma; Phase Ib includes people who have had prior therapy or none, while Phase II is for previously untreated patients. Key exclusions include symptomatic ascites or effusions needing treatment, active autoimmune disease or interstitial pneumonia, severe infection, recent major surgery, active tuberculosis in the past year, and serious cardiovascular or cerebrovascular disease. The trial is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This multicenter, open-label, single-group trial tests photodynamic therapy using Cosiporfin Sodium together with gemcitabine and cisplatin (GC) for people with locally advanced or recurrent metastatic extrahepatic cholangiocarcinoma that cannot be operated on. - It aims to preliminarily measure efficacy, focusing on the 6-month overall survival rate, and to assess safety and tolerability of the PDT plus GC treatment in patients with biliary obstruction. - Eligible participants are adults with histologically confirmed disease, inoperable or unwilling to have surgery, with biliary obstruction and at least one measurable lesion outside the bile ducts, plus good performance status and adequate organ function. - Key exclusions include ampullary cancer, brain metastases, major liver tumor burden (>50%), prior exposure to photosensitizers or PDT, prior systemic therapy in the recurrent/metastatic setting, unremovable biliary stents, active infections, and other conditions that could interfere with treatment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) is being studied. Conditions: Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer • Eligibility: Inclusion Criteria: 1. Patients with cytologically or histologically confirmed BTC by AJCC version 8. 2. Patients must have late stage (locally advanced, recurrent or metastatic) BTC. Patients must…. Goal: This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC). The study will include a safety run-in involving 6 study participants. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nataliya Uboha.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether camrelizumab (SHR-1210) plus apatinib can extend overall survival in people with advanced gastric or gastroesophageal junction adenocarcinoma whose disease progressed after first-line platinum-based therapy. It targets adults with metastatic or unresectable disease and PD-L1–positive tumors, who have good performance status and adequate organ function. The trial aims to learn if the combination is more effective and safe, and will collect PD-L1 biomarker data from tumor tissue. Key exclusions include active CNS metastases or autoimmune disease, uncontrolled cardiovascular issues, recent major GI bleeding or thrombosis, prior anti-PD-1/PD-L1 or VEGFR inhibitor therapy, and recent systemic therapy or unresolved adverse events.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Impact of Emotional Disorders on Response to Immune Checkpoint Inhibitor Therapy in Liver Cancer is being studied. Conditions: Liver Cancer, Emotional Disorder • Eligibility: Inclusion Criteria: * Age between 18 and 75 years, inclusive, regardless of gender. * Presence of at least one radiologically measurable lesion according to the Response Evaluation Criteria…. Goal: Hepatocellular carcinoma (HCC) carries a poor prognosis, with limited efficacy from current therapies including immune checkpoint inhibitors (ICIs). Concurrently, emotional distress (ED) is highly prevalent in cancer patients and is implicated in tumor progression via neuroendocrine-immune axis dysregulation (e.g., HPA axis activation, immunosuppressive TME). Phase/Status/Sponsor: Unknown phase; RECRUITING; Tongji Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Mayo Clinic-sponsored trial, currently recruiting, tests delivering cancer treatment at home versus in the clinic for adults with advanced cancer who are already receiving standard therapy. It aims to learn how the home-based approach affects patient experiences, preferences, comfort with home infusions, and overall quality of life compared with usual clinic care. The study also looks at safety of home administration with remote monitoring, and outcomes like emergency room visits, hospitalizations, and overall survival. Eligible participants are adults with various cancer types on eligible regimens, but those who need 24/7 assistance with daily activities, are currently inpatient, or have uncontrolled illness may be excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intravital Microscopy in Human Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm +20 • Eligibility: Inclusion Criteria: * Age ≥ 18 years of age * Eastern Cooperative Oncology Group (ECOG)Performance Status of ≤ 2 * Measurable tumor by direct visualization requiring surgical resection…. Goal: This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated with solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether ivonescimab is more effective than the standard second‑line chemotherapy FOLFOX for adults with advanced biliary tract cancer who progressed after first‑line treatment and who participated in SAFIR-ABC10. Participants are randomized 2:1 to receive ivonescimab every 3 weeks or FOLFOX, with the ivonescimab arm limited to up to 34 cycles. Treatments continue until disease progression or until the study limits are reached, and tumor responses are checked by imaging roughly every 6 weeks using RECIST v1.1. Key exclusions include contraindication to ivonescimab, unresolved toxicities from prior therapy, and conditions such as active HIV or TB, active autoimmune disease requiring systemic treatment, pregnancy, or recent major surgery.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma. is being studied. Conditions: Intrahepatic Cholangiocarcinoma (Icc) • Eligibility: Inclusion Criteria: * Histologically confirmed ICC (clinical stage I-III). * Undergoing curative-intent hepatectomy. * Availability of preoperative pasma or serum sample (≥200 µL). * Standard staging imaging completed…. Goal: Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking. The EXOMIC study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to detect occult metastasis preoperatively in patients with resectable ICC. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes is being studied. Conditions: Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms +76 • Eligibility: Inclusion Criteria: * Have a primary malignancy of the biliary tract, colon, liver, pancreas, peritoneum, rectum, small intestine, or stomach, with no plan for resection during the study…. Goal: Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Phase/Status/Sponsor: Unknown phase; RECRUITING; Cedars-Sinai Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether contrast-enhanced ultrasound (CEUS) can be used to evaluate how hepatocellular carcinoma (HCC) responds after transarterial radioembolization (TARE). - It is for adults with treatment-naïve HCC who are scheduled to undergo TARE. - The study will compare CEUS results with standard CT or MRI at about 1–2 months and 4–6 months post-TARE to see if CEUS can detect viable tumor earlier. - About 30 patients will be enrolled over 18 months across Jefferson Health sites, with at least 6 months of follow-up. - Exclusion criteria include medical instability or serious illness and known sensitivities to the ultrasound contrast agents Lumason or Sonazoid.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This randomized, multicenter trial tests UI-EWD (Nexpowder) hemostatic powder as the initial treatment, compared to conventional endoscopic therapies for nonvariceal upper GI bleeding. - It is for adults 22 years and older who have acute overt upper GI bleeding seen on endoscopy from ulcers with active bleeding or a visible vessel, tumors with bleeding, Dieulafoy lesions, or Mallory-Weiss tears. - The study aims to determine whether UI-EWD is noninferior to traditional therapy in stopping bleeding and reducing rebleeding when used first. - Key exclusions include pregnancy or nursing, inability to consent, recent endoscopic hemostatic treatment within 30 days, triple antithrombotic therapy, very low platelet count (<50 x 10^9/L), high INR (>3.5), and endoscopy not performed within 36 hours.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests the molecular and genetic basis of pediatric liver cancer by analyzing tumor tissue, blood, and saliva from affected children and their biological parents and siblings. It is for children under 21 who have had a liver tumor (benign or malignant) and their families. Researchers aim to learn how gene defects and gene function influence how these cancers develop and behave, to improve classification and future treatments. Exclusions include no prior or current treatment for a childhood liver tumor, and non-biological guardians or non-biological siblings.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer +1 • Eligibility: Inclusion Criteria Patients who meet ALL the following inclusion criteria will be eligible to participate in the study: 1. ≥18 years of age. 2. Histologically confirmed, locally advanced,…. Goal: The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work. Phase/Status/Sponsor: Unknown phase; RECRUITING; JiaRay Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of NX-1607 in Adults With Advanced Malignancies is being studied. Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer +11 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 years. * Measurable disease per disease-specific response criteria. * Patients must have disease that is metastatic or unresectable and have received…. Goal: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nurix Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * An adult 18 to 100 years of age, * Able to read English or Spanish at least an eighth-grade level, * From a racial/ethnic background…. Goal: The purpose of this study is to pilot test and evaluate an existing tailored ALEX (Agent Leveraging Empathy for eXams) Research Portal to navigate Black and Hispanic adult cancer patients and their family members through referral to cancer clinical trials. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a 3D biliary tract reconstruction tool and an AI algorithm to help endoscopists perform ERCP by creating 3D models from MRCP and CT scans. - It is for adults with biliary strictures who are treated with ERCP at Saint Antoine Hospital or Henri Mondor Hospital. - The study is retrospective and uses imaging data collected during routine care to develop and validate the software. - The goal is to see if the 3D models improve visualization and navigation during ERCP, with performance assessed by image-quality metrics and localization error, and without changing patient management. - Exclusion: patients who do not consent to reuse their data for research.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy Procedures is being studied. Conditions: Painless Gastrointestinal Endoscopy • Eligibility: Inclusion Criteria: * Age ≥18 years and ≤75 years, regardless of sex; * Patients scheduled to undergo painless gastrointestinal endoscopy examination or endoscopic surgery, which must include upper…. Goal: Gastrointestinal endoscopy procedures, including upper gastrointestinal endoscopy and colorectal endoscopy, represent a fundamental and important method for examining and managing digestive tract diseases, with both diagnostic and therapeutic applications. They are also utilized as effective tools for surveillance of gastrointestinal tumors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Jiao Tong University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Sigvotatug Vedotin in Advanced Solid Tumors is being studied. Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms +9 • Eligibility: Inclusion Criteria: * Disease indication * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on…. Goal: This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This early-phase trial tests a treatment for unresectable liver cancer using a patient’s own dendritic cells plus the Prevnar vaccine, given with immune checkpoint inhibitors after high-dose external beam radiotherapy. - It includes adults with hepatocellular carcinoma or intrahepatic cholangiocarcinoma that cannot be removed and have been treated with EBRT, with dendritic cells injected into the tumor and vaccines given alongside atezolizumab plus bevacizumab or atezolizumab plus tiragolumab. - The study aims to evaluate safety and tolerability and to estimate progression-free survival and other outcomes to see if this approach can stimulate the immune system and slow the cancer, compared with historical data. - Key exclusions include pregnancy or breastfeeding, immunocompromised status (including HIV), active infection or uncontrolled illness, autoimmune disease (with some exceptions), inability to stop anticoagulants for injections, and advanced liver disease (Child-Pugh B/C) or prior immune-modulating therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving Comprehensive Care of Cancer Patients is being studied. Conditions: Breast Cancer, Gastrointestinal Cancer, Hematologic Cancer • Eligibility: Inclusion Criteria: * For patients: 1) new diagnosis or within three months of treatment initiation for early-stage breast (I-IIIB), GI (Stage I-III), or hematologic (Stage I-III) cancer 2)…. Goal: Cancer survivors have unique healthcare needs, including managing serious late effects, ongoing surveillance, lifestyle modifications to reduce second cancer risk, and psychosocial support. Nearly 70% of survivors have at least one comorbid chronic condition in addition to cancer, which complicates the delivery of quality cancer care. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System is being studied. Conditions: Cancer, Cancer Central Nervous System, Cancer Thoracic +5 • Eligibility: Inclusion Criteria: * Able to comprehend and be willing to sign an informed consent form (ICF). * Diagnosis of local, loco-regionally advanced, or metastatic malignancy for whom radiotherapy…. Goal: The purpose of this prospective cohort study is to assess clinical and quality of life measures as well as to define the severity of adverse effects for the use of the RefleXion system to deliver intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), or SCINTIX Biology-guided radiotherapy (BgRT) in standard of care (SOC) use in the treatment of local,loco-regionally advanced, and oligometastatic malignancies. In addition, patient costs and charges will be analyzed to quantify the health economic impact of this modality. Phase/Status/Sponsor: Unknown phase; RECRUITING; RefleXion Medical.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a two-step, neoadjuvant treatment for intrahepatic cholangiocarcinoma (ICC): 12 weeks of capecitabine plus Selective Internal Radiation Therapy (SIRT) with Yttrium-90, given before surgery. - The goal is to see if this approach can shrink or downstage tumors so surgery is more feasible and potentially more successful, compared with upfront surgery. - It is for adults with histologically confirmed ICC that surgeons consider resectable but at high risk for close margins; key exclusions include severe liver disease or poor organ function, prior ICC chemotherapy, contraindication to hepatic artery catheterization, pregnant status, and other active cancers. - Participants are randomly assigned to the experimental neoadjuvant treatment or to the standard approach of immediate surgery, with long-term follow-up to compare outcomes.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a French multicenter, retrospective, observational study that is currently recruiting to study rare primary liver cancers. It includes adults 18 and older with histologically confirmed hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma, or hepatic angiosarcoma diagnosed after January 1, 2018. The study aims to describe clinical, histological and radiological features, collect tumor tissue and blood, and evaluate how treatments used in real-world care have performed to help determine the best sequencing of therapies. Key exclusions are lack of social security and no access to tumor tissue; living participants must consent to research for ancillary studies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer is being studied. Conditions: Liver Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer +2 • Eligibility: The following criteria must be met for subjects to be considered for the trial. Additional exclusion criteria must be met for subjects interested in the HepQuant subset of…. Goal: This is a pilot and feasibility study assessing the role of quantitative multiparametric MRI and blood-based biomarkers for the measurement of liver function in patients receiving radiation therapy for liver cancer, including hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver metastases regardless of primary histology, that are undergoing photon radiation either in the de-novo or re-irradiation setting. The goal of this study is to prospectively evaluate the feasibility of using quantitative multiparametric MRI to monitor liver function at baseline and following liver radiation therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Montefiore Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers is being studied. Conditions: Biliary Tract Cancer, Cholangiocarcinoma, Biliary Tract Neoplasms • Eligibility: Inclusion Criteria: * Measurable locally advanced, recurrent, or metastatic biliary tract carcinoma (including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma). * Patients with locally advanced disease…. Goal: This is a Phase 2 study to evaluate the efficacy, using objective response rate, of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous Tumor Infiltrating Lymphocytes (TIL) and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic biliary tract cancer. These are low-incidence cancers carry a poor prognosis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Udai Kammula.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China is being studied. Conditions: HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction • Eligibility: Participants must meet all the following inclusion criteria to be eligible for the study: 1. Participants with pathologically diagnosed locally advanced unresectable or metastatic gastric cancer/gastroesophageal junction adenocarcinoma…. Goal: Trastuzumab deruxtecan's (T-DXd's) efficacy and safety has been confirmed in traditional clinical trials, there is a lack of real-world evidence, especially among Chinese patients. The objective of this study is to evaluate real-world effectiveness and safety profile of T-DXd by collecting real-world data treating in patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Daiichi Sankyo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer is being studied. Conditions: Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer +5 • Eligibility: Inclusion Criteria: * Biopsy proven cancer of the pancreas, gallbladder or biliary tract, stomach, small bowel, colon, rectum, or appendix with extensive or irresectable peritoneal carcinomatosis * Estimated…. Goal: The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Hospital, Ghent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Advanced Cancer, Renal Cancer +15 • Eligibility: Major Inclusion Criteria: 1. Men and women 18 years of age or older. 2. 9 cohorts will be enrolled: * Cohort A1 / Exon 14 NSCLC MET inhibitor…. Goal: To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I) Phase/Status/Sponsor: Unknown phase; RECRUITING; Apollomics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Quality of Care in Relationship to Aborted Cancer Surgery is being studied. Conditions: Cancer, Gastrointestinal Cancer • Eligibility: Inclusion Criteria: * \>18 years * cancer patients with different gastrointestinal cancer diagnosis Exclusion Criteria: \- not able to answer the questionnarie SCNS-SF34 in Swedish.. Goal: Surgery is often a central curative treatment for gastrointestinal tumors. Surgical treatment of diagnosed cancer tumors is decided after a comprehensive assessment of the patient's physical status, radiological assessments and after careful evaluation at the multidisciplinary conference. Phase/Status/Sponsor: Unknown phase; RECRUITING; Linkoeping University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This multicenter, randomized, open-label trial tests whether adding prophylactic cholecystectomy to primary tumor surgery for midgut neuroendocrine tumors reduces biliary stone disease two years after surgery. - It is for adults with midgut NETs (jejunum, ileum, or proximal colon) who need primary tumor resection, with or without gallstones at baseline. - Participants are randomly assigned to either primary tumor resection alone or primary tumor resection plus prophylactic cholecystectomy and followed for 104 weeks (2 years). - The main goal is to measure the cumulated incidence rate of biliary stone disease after surgery. - Key exclusions include prior bowel resection or prior cholecystectomy, existing biliary stone disease, tumors outside the specified gut locations, and certain liver or gallbladder conditions that could affect safety or eligibility.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

City of Hope Medical Center is conducting a recruiting trial that tests an exosome-based liquid biopsy to distinguish hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (ICC). The test analyzes exosomal microRNAs in blood and uses machine learning to create a differential diagnosis panel. The goal is a noninvasive, cost-efficient test with high accuracy to guide treatment decisions before surgery. Eligible participants must have a histologically confirmed HCC or ICC and provide a pre-treatment blood sample; key exclusions include inability to consent, having both HCC and ICC, other primary liver cancers, or secondary liver cancer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer is being studied. Conditions: Gastrectomy for Gastric Cancer, Gastrectomy, MLH1 Gene Mutation +1 • Eligibility: Inclusion Criteria: * Patients who underwent elective gastrectomy for Stage I-IV gastric cancer. * Surgery performed at the General Surgery Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS.…. Goal: DNA methylation is one of the key mechanisms that are thought to underlie the association between aging and cancer. Several methylation-based measures of biological aging have been developed and have demonstrated an association with mortality and, in some cases, with cancer incidence. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a CLDN18.2-targeted PET imaging probe to visualize CLDN18.2 expression in tumors, using PET/MR or PET/CT, and also in healthy volunteers for safety. - It includes adults with suspected or confirmed gastric, pancreatic, bile duct, or other CLDN18.2-expressing cancers, plus healthy volunteers for pharmacokinetic study. - In cancer patients, the trial will assess how well CLDN18.2 PET detects tumor lesions, compare findings with histopathology, map location and metabolic features, and explore its use for guiding treatment decisions and predicting response versus FDG PET. - Exclusions include inability to complete scans, allergies to the imaging agent, significant comorbidities, and high fasting glucose (above 11.0 mmol/L) before FDG injection.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of LNCB74 in Advanced Solid Tumors is being studied. Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer +3 • Eligibility: Inclusion Criteria: 1. The participant provides written informed consent 2. ≥ 18 years of age on day of signing informed consent. 3. Participant with histologically or cytologically confirmed…. Goal: This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; NextCure, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of GC203 TIL in Advanced Malignant Solid Tumors is being studied. Conditions: Solid Tumor, Gynecologic Cancer, Breast Cancer +2 • Eligibility: Inclusion Criteria: * 1\. In the opinion of the Investigator, patients must be able to sign the ICF and complete all study-required procedures. 2\. Patients must be ≥18…. Goal: A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Juncell Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MT-4561 in Patients With Various Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer +13 • Eligibility: Main Inclusion Criteria: Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable…. Goal: This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tanabe Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence is being studied. Conditions: Biliary Tract Cancer, Cholangiocarcinoma • Eligibility: Inclusion Criteria: 1. Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures. 2. Female and…. Goal: PURITY is a multicentre, randomized adaptive phase II/III trial aimed at comparing the triplet combination of gemcitabine, cisplatin and nabpaclitaxel as neoadjuvant treatment (ARM A) versus standard upfront surgery (ARM B) in terms of 12-month PFS rate (phase II part) and PFS (phase III part) in patients with resectable BTC at high risk for recurrence. Phase/Status/Sponsor: Unknown phase; RECRUITING; Gruppo Oncologico del Nord-Ovest.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a streamlined approach to transarterial radioembolization (TARE) for liver cancer, using SIR-Spheres in a same-day, single-session procedure without full pre-procedural nuclear imaging for eligible patients. - It is for adults with metastatic liver cancer or cholangiocarcinoma whose largest tumor is 7 cm or smaller, up to five tumors, enough healthy liver tissue, good liver function (Child-Pugh A), and good performance status (ECOG ≤1). - The study aims to determine if this faster method can be safely delivered, with predefined dosing rules (lung shunt assumed 5%, lung dose ≤10 Gy) and post-treatment dosimetry the next day, followed for one year. - Exclusions include hepatic vein invasion or hepatic vein enhancement, dysmorphic intratumoral vessels >3 mm, TIPS, major portal vein issues, biliary stents, allergy to contrast, or other factors that could raise the risk of radiation pneumonitis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer is being studied. Conditions: Gastric Cancer Stage IV • Eligibility: Inclusion Criteria: 1. Provided written informed consent for treatment. 2. Age ≥ 19 years old 3. measurable or evaluable disease based on RECIST 1.1. Lesions 4. Eastern Cooperative…. Goal: Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Olaparib is a potent PARP inhibitor (PARP1, 2, and 3) that is being developed as a monotherapy as well as for combination with chemotherapy, ionizing radiation, and other anti-cancer agents including novel agents and immunotherapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Yonsei University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study is being studied. Conditions: Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma, Perihilar +6 • Eligibility: Inclusion Criteria: * person older than 18 years, who has known extrahepatic cholangiocarcinoma and is indicated for ERCP Exclusion Criteria: * disagreement with the study. Goal: Diagnosis of extrahepatic cholangiocarcinoma is challenging because the yield of imaging and tissue sampling is limited. Raman spectroscopy is an optical method based on the analysis of scattered monochromatic light. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Hospital Olomouc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing is being studied. Conditions: Lung Cancer, Breast Cancer, Gastric Cancer +1 • Eligibility: Inclusion Criteria: 1. 18 to 75 years old, regardless of gender. 2. Score of nutrition risk screening 2002 (NRS2002) is less than 3, NRS20023. 3. Advanced and unresectable…. Goal: To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Liu Huang.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Liver Cancer Registry Platform is being studied. Conditions: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma • Eligibility: Inclusion criteria: * Confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) als early, intermediate or advanced/metastatic stage * Age ≥ 18 years * Signed and dated informed consent (IC):…. Goal: The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma (CCC) in Germany. Phase/Status/Sponsor: Unknown phase; RECRUITING; iOMEDICO AG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests the safety of delivering nab-paclitaxel directly into the abdomen with pressurized intraperitoneal aerosolization (PIPAC) together with gemcitabine and cisplatin for biliary tract cancers that have spread to the peritoneum. - It is for adults with biliary tract cancer and visible peritoneal metastases who meet health criteria. - The study aims to learn about safety and how well the treatment works, including overall survival, progression-free survival, surgical outcomes after the PIPAC procedure, and patients’ quality of life and daily functioning. - Key exclusions include prior systemic therapy for advanced disease, substantial liver involvement, brain metastases, pregnancy, and other serious health conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Participants have histologically proven advanced solid tumors with known prevalent and high Ly6E expression, Disease characteristic: Participants should have an unresectable locally advanced or metastatic…. Goal: The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC). Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; EMD Serono Research & Development Institute, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a first-line treatment for unresectable intrahepatic cholangiocarcinoma using FOLFOX-based hepatic arterial infusion chemotherapy with donafenib and pucotenlimab. - It is a prospective, open-label, single-arm phase II study and is not yet recruiting. - The primary goal is to measure the objective response rate, with secondary goals including progression-free survival, overall survival, disease control rate, and safety. - Eligible participants are adults up to 75 years old; key exclusions include prior anti-PD-1/PD-L1 therapy, active CNS metastases, autoimmune disease requiring systemic treatment, active infection, HBV DNA > 2000 IU/mL, HIV, syphilis, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This not-yet-recruiting trial (AROMA2) tests a non-invasive breath test for oesophagogastric cancer by boosting volatile markers with a simple nutrient drink and measuring breath VOCs. It is for adults 18 and older referred from primary care with suspected upper GI cancer, across 20+ centers, in a triple-blinded design to assess diagnostic accuracy. Breath samples are collected before and after the oral stimulant drink and analyzed with GC-MS to determine sensitivity and specificity. Exclusions include previous oesophageal or gastric surgery, cancer in the last three years (except non-melanoma skin cancers), pregnancy, and allergies to constituents of the nutrient drink.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers is being studied. Conditions: Liver Cancer, Biliary Tract Cancer, Pancreatic Cancer • Eligibility: Criteria: Inclusion Criteria for Cancer Arm Participants: Age 40-75 years at the day of consenting to the study. Able to provide a written informed consent. Pathologically confirmed liver,…. Goal: LIBRARY is a prospective, multi-center, observational study aimed at detecting early liver, biliary tract, and pancreatic cancers by combining assays of cell-free DNA (cfDNA) methylation, serum protein, and microRNA. Phase/Status/Sponsor: Unknown phase; RECRUITING; Second Affiliated Hospital, School of Medicine, Zhejiang University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests PSMA-targeted imaging and PSMA expression in biopsy tissue for patients with newly diagnosed gastroenterologic tumors. It aims to see if PSMA-PET can detect more disease sites than standard imaging and whether the PSMA signal can predict outcomes under guideline-based treatment. Eligible participants are adults with newly diagnosed GET before starting guideline-compatible anti-tumor therapy, with available tumor tissue and the ability to consent and follow up. Exclusions include curative-intent treatment, insufficient tumor tissue, history of other cancers, pregnancy or breastfeeding, contraindications to PET/CT, and men with prostate cancer. The study is sponsored by Würzburg University Hospital and is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors is being studied. Conditions: Esophageal Cancer, Gastric Cancer, Pancreatic Cancer +2 • Eligibility: Inclusion Criteria: 1. Voluntarily sign the informed consent and follow the requirements of the protocol; 2. No gender limit; 3. Age: ≥18 years old and ≤75 years old…. Goal: This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in locally advanced or metastatic HER2 positive/lower expression gastrointestinal cancer and other solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sichuan Baili Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories is being studied. Conditions: Bile Duct Adenocarcinoma, Bile Duct Carcinoma • Eligibility: Inclusion Criteria: 1. Provision to sign and date the consent form; 2. Adult patients ≥ 21 years old; 3. Any patient who is required to undergo endoscopic retrograde…. Goal: This study plans to enroll up to 75 research subject who have a biliary disorder such as bile duct stones or intermediate biliary strictures. The purpose of this research is to assess whether the Dragonfly™ Pancreaticobiliary Scope functioned as intended in combination with the commercially available accessories during your scheduled endoscopy procedure. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Colorado, Denver.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MetBio-GC tests metabolic biomarkers to help with early diagnosis, prognosis, and prediction of recurrence and metastasis in gastric cancer, using metabolomics. It is a prospective observational study enrolling adults with gastric cancer and healthy controls to build and validate a metabolite database and biomarker panel for screening and prognostic use. The study aims to learn whether these metabolic markers can provide a safe, convenient, and sensitive way to detect gastric cancer early and forecast outcomes. Key exclusions include healthy controls with high hereditary cancer risk or chronic diseases, recent antibiotics/probiotics, pregnancy, or current participation in another trial; gastric cancer participants with ongoing interventional treatment, other recent cancers, poorly controlled comorbidities, or medications that affect metabolism.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer is being studied. Conditions: Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer +1 • Eligibility: Inclusion Criteria: Age 18-75 years at time of enrollment; Histologically or cytologically confirmed advanced or metastatic biliary tract adenocarcinoma (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder carcinoma); Unresectable locally…. Goal: Brief Summary: This study is for patients with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The purpose is to find out if using anti-blood vessel formation drugs after immunotherapy treatment can help patients live longer without their cancer getting worse. Phase/Status/Sponsor: Unknown phase; RECRUITING; First Affiliated Hospital of Zhejiang University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether eccDNA biomarkers found in bile can help diagnose malignant biliary strictures. - It is for adults with suspected indeterminate biliary stricture who are planned to undergo ERCP. - The study aims to learn how accurately these eccDNA markers can distinguish malignant from non-malignant stricture causes. - Key exclusions include ERCP failure or inability to obtain bile, severe comorbidities, predicted survival less than 1 year due to another disease, or inability to comply with the protocol or follow-up. - The study is sponsored by Peking University Third Hospital and is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer is being studied. Conditions: Stomach Neoplasms • Eligibility: Inclusion Criteria: 1. 20 years ≤ age ≤ 80 years 2. The primary gastric lesions were located in the proximal third of the stomach 3. histologically proven gastric…. Goal: Proximal early gastric cancer can choose radical total gastrectomy or proximal gastrectomy. The patients have poor nutritional status and quality of life after total gastrectomy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests adding elimusertib (BAY 1895344) to standard chemotherapy with cisplatin, or cisplatin plus gemcitabine, for adults with advanced solid tumors, including urothelial cancer. It is a dose-escalation phase I trial to find the safest and most effective dose and to learn how the combination behaves in the body. The trial will assess safety and tolerability, identify the maximum tolerated dose, and collect pharmacokinetics and early signs of activity, with a focus on urothelial cancer in the triplet arm. Eligible participants are adults 18 or older with measurable advanced disease for which cisplatin-based therapy is suitable; key exclusions include pregnancy, life expectancy under 6 weeks, uncontrolled illness, recent chemotherapy or radiotherapy, and certain drug interactions or prior ATR inhibitors. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer is being studied. Conditions: Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer • Eligibility: Inclusion Criteria: * Patient must be \>= 18 years of age * Patient must have a histologically confirmed diagnosis of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) at the local laboratory…. Goal: This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab in treating patients with liver cancer that cannot be removed by surgery (unresectable) or that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests the combination of nivolumab and ipilimumab in adults with rare cancers to see if it can shrink tumors or slow their growth. - It includes many different rare tumor types in separate groups, plus a PD-L1–amplified cohort that uses nivolumab alone, and it measures how often tumors respond using standard criteria. - The trial also looks at safety, overall survival, and progression-free survival across cohorts. - Eligible participants must have progressed after prior therapy and generally cannot have active brain metastases or uncontrolled autoimmune disease; some cohorts have additional specific requirements or exclusions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

First in Human Study of QLS5316 in Solid Tumors is being studied. Conditions: Solid Tumors, Colorectal Cancer, Gastric Cancer or Gastroesophageal Junction Adenocarcinoma +2 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years 2. Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1 3. Life expectancy ≥ 3 months; 4. Measurable disease per RECIST v1.1…. Goal: This is a first-in-human (FIH) Phase I, multi-center, open-label, study of QLS5316, in patients with advanced solid tumors. The study aim to evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and immunogenicity of QLS5316 as monotherapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Qilu Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a prospective, open-label, randomized trial testing whether a tailored geriatric intervention based on frailty assessment helps elderly gastric cancer patients tolerate surgery and adjuvant chemotherapy. - It is for patients aged 65 and older with locally advanced (stage II–III) gastric cancer who are planned for curative gastrectomy and will receive adjuvant chemotherapy within 4–8 weeks after surgery. - All participants will have a frailty assessment within 7 days before starting treatment, followed by personalized geriatric interventions; the study will compare frail and non-frail patients on postoperative complications, chemotherapy tolerance, toxicity, and quality of life. - Exclusions include cognitive impairment or inability to cooperate, concurrent other anticancer treatments, and having multiple cancers requiring treatment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests the safety, feasibility, and potential effectiveness of single-port robot-assisted radical gastrectomy for gastric cancer. - It is for adults aged 18 to 75 with histologically confirmed gastric adenocarcinoma who are candidates for potentially curative surgery and have good performance status. - It is a single-center, phase 2a exploratory study following the IDEAL framework, and recruitment has not yet begun. - Possible participants would be excluded if pregnant or lactating, had prior major upper abdominal surgery or certain stomach procedures, recently received cancer treatment, or have other serious health conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer is being studied. Conditions: Biliary Tract Cancer (BTC) • Eligibility: Inclusion Criteria: Subjects must meet all of the following criteria to be enrolled in this study: 1. No gender restriction, age ≥18 years, and expected survival ≥3 months;…. Goal: This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the impact of Yueju Pill on quality of life and treatment efficacy in patients with advanced biliary tract cancer (BTC) receiving standard therapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests whether combining bile-based molecular testing with standard biliary brush cytology/biopsy can improve detection of malignant biliary strictures. It is for adults aged 18–90 who have indeterminate biliary strictures and have undergone ERCP with biliary biopsy and/or brush cytology. Researchers will collect bile and screen for molecular markers using multi-omics to develop and validate a bile-based diagnostic model. Exclusions include coagulation disorders, pregnancy, other cancers not related to biliary strictures, or those who decline participation. The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study is a prospective randomized trial comparing two ERCP cannulation techniques: Precut needle-knife precut versus the Intentional Double Guidewire Technique. It targets adults with biliary obstruction who need ERCP and have a native papilla with difficult cannulation (per ESGE 5-5-2). The goal is to learn which method provides better biliary access and has a safer profile during difficult cannulation. Eligible participants are adults over 18 with benign or malignant obstruction and no prior sphincterotomy; key exclusions include ampullary mass, surgically altered anatomy, uncorrectable coagulopathy, or acute pancreatitis before ERCP.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether adding serplulimab to FLOT chemotherapy improves the rate of complete tumor disappearance (pCR) in adults with stage III gastric adenocarcinoma. It compares serplulimab plus FLOT versus FLOT alone in a randomized design, for patients whose tumors are PD-L1 positive (CPS ≥ 1). Participants receive treatment every two weeks, have imaging at 4 and 8 weeks, then undergo surgery and may receive postoperative serplulimab with adjuvant chemotherapy or adjuvant chemotherapy alone. Key exclusions include HER2-positive tumors, MSI-H/dMMR, autoimmune disease, prior gastric cancer treatment, active infection or pregnancy. Status: ACTIVE_NOT_RECRUITING (the trial is active but not recruiting).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. is being studied. Conditions: Biliary Tract or Colorectal Cancer With Her2-positive/Mutated • Eligibility: Inclusion Criteria: 1. Metastatic and/or unresectable advanced colorectal adenocarcinoma, or locally advanced, recurrent, metastatic and/or unresectable advanced biliary tract carcinoma 2. HER2 positive or HER2 gene mutation; 3.…. Goal: To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Pharmaceuticals Holding Co., Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding peginterferon alfa-2b to standard nucleos(t)ide analogue therapy can reduce recurrence of HBV-related liver cancer after radical treatment. - It is for adults aged 18-70 who are HBV surface antigen positive and have hepatocellular carcinoma treated with surgery or ablation, with good liver function (BCLC 0-A, Child-Pugh A). - The study is single-center, non-randomized, open-label, comparing NAs alone versus NAs plus peginterferon alfa-2b to see if it lowers the 3-year recurrence rate and may improve cure. - Participants will undergo regular imaging and blood tests every few months to monitor recurrence and safety. - Key exclusions include prior systemic cancer treatments, other active cancers, allergy to interferon, severe liver or kidney disease, autoimmune disease, pregnancy, or participation in other trials.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator will collect real-world data on using direct cholangiopancreatoscopy, performed by a single operator, for biliary and pancreatic duct problems. It will enroll adults undergoing this procedure at participating centers starting June 1, 2025. The study aims to confirm technical feasibility, assess effectiveness and safety, and evaluate cost-effectiveness to determine where in the clinical pathway this technique should be used. Eligibility requires age 18 or older, signed informed consent, and the ability to follow up; those under 18, without consent, or with follow-up is not possible are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Proteomic Profiling to Differentiate Pancreatic and Biliary Adenocarcinomas is being studied. Conditions: Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * Patients ≥ 18 years old * Pancreaticoduodenectomy for pancreatic adenocarcinoma or distal cholangiocarcinoma * Patient's non-opposition to the reuse of data Exclusion Criteria: * Neoadjuvant…. Goal: Distal cholangiocarcinoma and pancreatic adenocarcinoma are aggressive cancers with overlapping diagnostic features, making them challenging to differentiate. Although both require similar surgical treatment, their postoperative chemotherapy regimens differ significantly, with capecitabine used for distal cholangiocarcinoma and modified FOLFIRINOX for pancreatic adenocarcinoma, based on distinct guidelines. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University Hospital, Bordeaux.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study compares two ways to reconnect the stomach to the intestine after distal gastrectomy for gastric cancer: Roux-en-Y (REY) and Billroth II (B2). - It is for adults with distal gastric cancer treated with curative distal gastrectomy who have no distant metastasis. - The goal is to find out which reconstruction method improves health-related quality of life, focusing on eating, reflux, and pain, using the QLQ-C30 and QLQ-OG25 questionnaires over two years, with one endoscopy at year 1. - Participants are randomly assigned to REY or B2; key exclusions include preoperative metastasis, palliative surgery, pregnancy, and inability to consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers is being studied. Conditions: Breast Cancer, Liver Cancer, Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: * \- Age \>18 years. * Advanced disease status ("unresectable" or "metastatic"). * Patient included either at the time of diagnostic investigation or during first line…. Goal: The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs and to accelerate clinical research in cancers. * Accordingly, this project aims to study the contribution of early systematic multigene sequencing (NGS) discussed in Molecular Tumour Board for poor prognosis cancers, with no current indication for early sequencing. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University Hospital, Lille.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer is being studied. Conditions: Biliary Tract Cancer (BTC) • Eligibility: Inclusion Criteria: 1. Provide written informed consent prior to any study procedures and agree to adhere to all protocol requirements 2. Aged at least 18 years. 3. Has…. Goal: The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS). Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to receive either 60 mg D07001-softgel, 100 mg D07001-softgel, or placebo, combine with capecitabine. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; InnoPharmax Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Liver Cancer Prognosis Investigation Study is being studied. Conditions: Liver Neoplasms • Eligibility: Inclusion Criteria: * Age 18-80 years, * Diagnosed with primary liver cancer (ICD-10: C22) (Referring to the diagnostic criteria in the "Primary Liver Cancer Diagnosis and Treatment Guidelines…. Goal: This prospective cohort study is designed to explore the role of environmental, clinical, and genetic risk factors in the progression and prognosis of primary liver cancer (PLC). We will recruit 5000 patients with newly diagnosed, previously untreated PLC. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests pimitespib in combination with imatinib for patients with gastrointestinal stromal tumors (GIST) that have progressed on imatinib. - It has a dose-escalation part to find the maximum tolerated dose and the recommended dose, while assessing safety, pharmacokinetics, and early antitumor activity, followed by an expansion part with three arms. - Arm A evaluates the combination in patients who progressed on imatinib at doses below the determined MTD; Arm B tests pimitespib alone and also explores giving imatinib after pimitespib; Arm C uses sunitinib monotherapy as a reference. - Eligibility includes histologically confirmed GIST, radiographic progression on or after imatinib, at least one measurable lesion, and ECOG 0-1 with informed consent. - Exclusion criteria include severe vision impairment, prior therapy beyond imatinib for advanced GIST, prior extensive gastrectomy or small-bowel resection, serious illness, other active cancers, and pregnancy or lactation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients is being studied. Conditions: Head and Neck Cancer, Urologic Cancer, Lung Cancer +2 • Eligibility: Inclusion Criteria: * 18 years of age or older * Histologic, cytologic or imaging confirmation of a malignancy in accordance with targeted indications * Written informed consent signed…. Goal: The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma. Innate Pharma is a biotechnology company which discovers and develops therapeutic antibodies that exploit the innate immune system to improve cancer treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Assistance Publique Hopitaux De Marseille.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer is being studied. Conditions: Bile Duct Cancer • Eligibility: Inclusion criteria 1. Male or female ≥18 years old. 2. Histologically or cytologically confirmed diagnosis of previously untreated and unresectable\*, locally advanced and/or metastatic extrahepatic biliary tract cholangiocarcinoma…. Goal: The goal of this clinical trial is to provide evidence for the general tolerability of radiofrequency ablation (bRFA) in patients with unresectable bile duct cancer undergoing systemic palliative treatment consisting of chemotherapy (gemcitabine and cisplatin) plus durvalumab (immune-checkpoint-inhibitor, ICI). The main question it aims to answer is whether it is safe to combine chemotherapy (gemcitabine and cisplatin) and immunotherapy (durvalumab) - CICI therapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Insel Gruppe AG, University Hospital Bern.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers is being studied. Conditions: Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer +3 • Eligibility: Diagnosis and Main Criteria for Inclusion/Exclusion: Inclusion Criteria Main Study - patients with MSS mCRC These criteria are applicable for both Dose Escalation and Expansion part of the…. Goal: This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Rottapharm Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests S095029, an anti-NKG2A antibody, given with pembrolizumab to treat MSI-H/dMMR gastric or gastroesophageal junction adenocarcinoma that is locally advanced and unresectable or metastatic. - It has two parts: a safety lead-in to find the recommended dose, and a later expansion to assess anti-tumor activity and safety. - Eligible participants have MSI-H/dMMR-confirmed locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma. - Key exclusions include more than one prior treatment in this setting, prior checkpoint inhibitor therapy, recent systemic anticancer therapy within 4 weeks, recent radiotherapy within 2 weeks, or major surgery within 4 weeks or not recovered.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers is being studied. Conditions: Gastrointestinal Cancers, Frailty, Sarcopenia in Elderly +8 • Eligibility: Inclusion Criteria: * Age ≥65 years * Histologically confirmed non-metastatic or locally advanced gastrointestinal cancers (esophageal, gastric, colorectal, pancreatic, biliary tract) * Planned to receive adjuvant chemotherapy (standard…. Goal: This study evaluates the effectiveness of the G8 and VES-13 frailty scales in predicting chemotherapy-related toxicity in older patients with gastrointestinal cancers receiving adjuvant chemotherapy. Older adults are more vulnerable to treatment-related side effects due to age-related declines in physiological reserve. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Ankara Etlik City Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests how liver cancer (hepatocellular carcinoma, HCC) patients respond to interventional therapy combined with systemic therapy and how outcomes vary between individuals. It will look at outcomes like disease control, progression-free survival, patient-reported outcomes, and adverse reactions, and it will study clinical features and biomarkers that relate to this heterogeneity. The goal is to build a machine learning model to predict the risk of adverse reactions to help tailor decisions for each patient. The study is not yet recruiting and will enroll adults with HCC who are receiving or planning interventional therapy with systemic treatment (including DEB-TACE with targeted therapy and/or immunotherapy) or other local interventional treatments; it excludes people with other active cancers, severe cognitive impairment, very limited life expectancy, or decompensated liver function (Child-Pugh C).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Postbiotics for Mitigation of Postoperative Dysbiosis in Gastrointestinal Cancer Surgery is being studied. Conditions: Colon Cancer, Gastrointestinal Cancer • Eligibility: Inclusion Criteria: 1. Recently diagnosed with nonmetastatic GI cancer, including but not limited to small bowel, colon, rectal, pancreatic, gastric, or hepatic malignancies, and scheduled for an elective…. Goal: To measure the efficacy of postbiotic supplements in mitigating the gut dysbiosis induced by colon cancer surgery. Efficacy in mitigating dysbiosis will be measured by the change in fecal Shannon Diversity Index (SDI) within patients from the baseline sample to various postoperative timepoints. Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; University of South Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether adding the antidepressant fluoxetine to immunotherapy improves outcomes for people with advanced liver and gallbladder cancers. It is for adults 18 to 80 who have liver cancer or bile duct cancer that has spread or is locally advanced and who are about to start PD-1/PD-L1 inhibitor therapy, and who have depression or anxiety. The researchers want to learn if fluoxetine can better control the cancer, extend survival, and also improve mood and quality of life. Exclusions include active hepatitis B or C infection, a history of serious mental illness, fluoxetine allergy, or inability to take oral medications.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies is being studied. Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer +10 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 at the time of screening * Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and…. Goal: This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This randomized phase III trial tests whether adding gastrectomy with cytoreductive surgery and HIPEC improves outcomes for gastric cancer patients with limited peritoneal spread. It is for adults with a resectable primary tumor (cT3-c4) and limited peritoneal carcinomatosis or positive peritoneal cytology who have not shown progression on prior chemotherapy. Participants are randomly assigned to the experimental treatment or to standard palliative systemic chemotherapy, and the study aims to learn about overall survival. Key exclusions include distant metastases, recurrent gastric cancer, prior gastric tumor resection, non-synchronous peritoneal carcinomatosis, active infection, or other serious medical conditions that could interfere with treatment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer is being studied. Conditions: Unresectable Biliary Tract Cancer • Eligibility: Inclusion Criteria: 1. Histologically documented locally advanced or metastatic BTC (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma) not previously treated with palliative systemic therapy or radiation…. Goal: You are being asked to take part in this study because you have a biliary cancer that is incurable and has spread to other organs. Chemotherapy is often used to help shrink the cancer temporarily and may improve survival. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AHS Cancer Control Alberta.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether Comprehensive Geriatric Assessment (CGA) with tailored perioperative care can reduce postoperative morbidity after major liver resection or pancreaticoduodenectomy for cancer in older adults. - It is for people aged 70 and older with hepatobiliary or pancreatic cancers who need these surgeries. - The study aims to learn if CGA can lower complications and improve quality of life after surgery. - Exclusions include not having access to the French health system, inability to consent, participation in a double-blind randomized trial, or being legally protected.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The ANTARES study is testing whether nivolumab, a PD-1 blocker, can work in people with advanced or metastatic rare tumors that express PD-L1 (CPS ≥ 10), regardless of tumor type. It is a phase II basket trial, enrolling adults whose cancers have higher PD-L1 expression after standard treatments have failed. Treatment can last up to 12 months, and researchers will look at objective responses, progression-free survival, and biomarkers like PD-L1, ctDNA, and microvesicles. Exclusions include prior immunotherapy, pregnancy or breastfeeding, active infection, autoimmune disease (with limited exceptions), and uncontrolled CNS metastases, among other health criteria.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dachengqi Decoction for Enhancing Early Gastrointestinal Recovery After Whipple Surgery is being studied. Conditions: Whipple Operation • Eligibility: Inclusion Criteria: * Patients aged 18-75 years, regardless of gender (n=45); * Meeting American Society of Anesthesiologists (ASA) physical status classification I-II criteria, scheduled to undergo pancreaticoduodenectomy or…. Goal: To investigate the clinical efficacy of the traditional Chinese medicine formula Dachengqi Decoction in promoting early gastrointestinal function recovery after Whipple surgery, and to evaluate its impact on postoperative nutritional status, hospitalization duration, and complication rates, thereby providing evidence for optimizing postoperative rehabilitation strategies in pancreaticoduodenectomy patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; China-Japan Friendship Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Extracellular RNA Markers of Liver Disease and Cancer is being studied. Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer, Cirrhosis +1 • Eligibility: Inclusion Criteria: * Lab results from within the previous 90 days. * Diagnosis of HCC or biliary tract cancer * Diagnosis of cirrhosis based on histology, imaging, or…. Goal: The study will examine and evaluate the use of extracellular RNA in blood as markers for the diagnosis of liver disease or cancer, and as markers for prediction of response to treatment or recurrence of cancer after surgery Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer is being studied. Conditions: Cholangiocarcinoma, Gall Bladder Carcinoma • Eligibility: All enrolled patients will postoperatively be assessed for eligibility for the treatment phase. Additionally patients not previously enrolled into the trial for whatever reason (e.g. incidental finding during…. Goal: This is a multicenter, prospective, randomized, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation vs. standard of care (observation alone in stage 1 and capecitabine and observation in stage 2) in patients after curative intent resection of BTC. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Universitätsklinikum Hamburg-Eppendorf.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer is being studied. Conditions: Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer +1 • Eligibility: Inclusion Criteria: * Advanced solid tumor * Measurable disease, per RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Adequate organ function Exclusion Criteria: *…. Goal: This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; TORL Biotherapeutics, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether detecting cell-surface plectin on ERCP-obtained biliary samples can improve diagnosis of cholangiocarcinoma. It is for patients who have a biliary stricture or mass seen on imaging and are already undergoing ERCP as part of their usual care. During ERCP, participants will have an extra biopsy or brush sample analyzed to see if cell-surface plectin can be detected and whether this is more sensitive than standard cytology alone. The trial is not recruiting yet, and key exclusions are being under 18 years old or unable to consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma +9 • Eligibility: Key Inclusion Criteria: * Subject has a histologically- or cytologically-diagnosed solid tumor which is advanced or metastatic and which has progressed on or following at least one systemic…. Goal: This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Cybrexa Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations is being studied. Conditions: Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast • Eligibility: Inclusion Criteria: * Adults ≥18 years old. Other age restrictions may apply as per local regulations. * Unresectable and/or metastatic solid tumors with pre-specified HER2 mutations (S310F, S310Y,…. Goal: This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are patients who have progressed following prior treatment or who have no satisfactory alternative treatment options, including approved second line therapies in the specific tumor type. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests Trilaciclib to protect the bone marrow from chemotherapy in people with advanced biliary tract cancer (cholangiocarcinoma) or pancreatic cancer. It is for adults 18 and older who need chemotherapy and have a confirmed diagnosis, with enough health and follow-up ability. The study aims to learn about Trilaciclib’s safety and whether it reduces chemotherapy-related bone marrow suppression. Major exclusions include history of certain myeloid blood disorders, active brain metastases, pregnancy or lactation, recent major surgery or radiotherapy, and known allergy to the study drug.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving a Bile Duct Drainage Procedure in Patients With Inoperable Cancer Blocking the Bile Ducts: Comparing Two Types of Endoscopically Placed Internal Stents to Prevent Blockage of a Lumen Apposing Metal Stent is being studied. Conditions: Malignant Biliary Obstruction, Advanced Pancreatic Cancer and Cholangiocarcinoma, Inoperable Malignant Biliary Obstruction +1 • Eligibility: Inclusion Criteria: * Age ≥18 years. * Radiologically or histologically proven malignant distal bile duct obstruction with unresectable or metastatic disease, including those who have already failed ERCP…. Goal: This study looks at the best way to treat bile duct blockage in people with advanced cancer that cannot be removed by surgery. A blocked bile duct can cause serious symptoms like yellowing of the skin (jaundice), infection, and pain. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Waikato Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer is being studied. Conditions: Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma +7 • Eligibility: Inclusion Criteria: * Pathologically confirmed biliary tract cancer, having received at least 1 prior line of systemic therapy, and received no more than 2 prior lines of therapy…. Goal: This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial is being studied. Conditions: Hepatocellular Carcinoma (HCC) • Eligibility: Inclusion Criteria: 1. Age 18 years or older, gender unlimited; 2. Subjects for whom sufficient blood samples can be obtained (whole blood volume not less than 10 mL);…. Goal: This clinical trial aims to systematically evaluate the clinical performance and accuracy of the HepaAiQ test kit, a multi-gene methylation assay based on PCR with fluorescent probe detection. The test results are compared against clinical reference standards, including pathological and/or imaging diagnoses, to assess the product's diagnostic performance. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Singlera Genomics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This expanded access program provides ulixertinib (BVD-523) for compassionate use in people with advanced MAPK pathway–altered solid tumors (including KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations). It is for patients aged 12 and older who have exhausted or not adequately benefited from standard cancer therapies, and it may be given alone or with other tolerable drugs. The goal is to make ULIXERTINIB available and monitor safety and how well patients tolerate it in real-world use. Key exclusions include currently being enrolled in another ulixertinib trial, recent systemic therapy or radiotherapy within defined windows, history of retinal vein occlusion or central serous retinopathy, pregnancy or breastfeeding, significant uncontrolled illness, prior stomach/duodenal surgery affecting absorption, and use of certain interacting medications (strong inhibitors/inducers of CYP1A2, CYP2D6, or CYP3A4).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests peposertib together with avelumab and hypofractionated radiation therapy in adults with advanced or metastatic solid tumors and hepatobiliary cancers. - It aims to find a safe dose and assess how well this combination works, with Phase II focusing on hepatobiliary tumors and comparing against avelumab plus radiation alone by measuring objective response rate. - The study will also look at how the drugs are processed in the body and collect biomarker data to understand who may respond. - Eligibility notes include that Phase I excludes prior immune checkpoint therapy, while Phase II has some allowed prior checkpoint exposure under specific conditions; pregnancy is not allowed and certain autoimmune or CNS conditions exclude participation. - The study status is currently suspended.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tested the [18F]FAPI-74 PET scan to detect FAP-expressing cells in people with gastrointestinal cancers, including liver cancer, cholangiocarcinoma, gastric, pancreatic, and colorectal cancer. - It enrolled adults with confirmed GI cancers and used the PET scan after initial staging, comparing PET results with FAP immunohistochemistry as the primary objective and with histopathology as the secondary objective. - Participants needed a tissue sample from biopsy or planned biopsy/resection, no cancer treatment between tissue sampling and the PET scan, and informed consent. - Exclusions included pregnancy or breastfeeding, infections or serious illnesses that could affect FAP expression, recent use of another investigational agent, and known hypersensitivity to components of the tracer. - The study is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy is being studied. Conditions: Melanoma, Gastrointestinal Neoplasms, Genitourinary Cancer +2 • Eligibility: Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent 2. Diagnosed with non-small cell lung cancer (NSCLC) OR melanoma AND initiating therapy with single…. Goal: This research aims to identify clinical strategies to manage adverse events during immune checkpoint inhibitor therapy by (1) determining the impact of checkpoint inhibitors on metabolism through major CYP enzymes and (2) identifying associations between pro-inflammatory cytokine concentrations and negative clinical outcomes during checkpoint inhibitor therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Indiana University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tested whether adding hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil to biliary drainage improves survival for people with locally advanced, unresectable perihilar cholangiocarcinoma (pCCA). - It compared biliary drainage plus this chemotherapy approach against biliary drainage plus best supportive care. - Participants were adults aged 18–80 with locally advanced unresectable pCCA, good performance status, and adequate liver function; key exclusions included allergy to contrast or 5-FU, pregnancy, prior chemotherapy or radiotherapy, metastases, and serious comorbidities. - The study has completed and aimed to determine whether the combined treatment provides a survival benefit and acceptable safety.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors is being studied. Conditions: Gastric Cancer, Colorectal Cancer • Eligibility: Inclusion Criteria: * Has a pathologically or cytologically documented advanced/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma and colorectal cancer that is refractory to or intolerable with standard…. Goal: This is a single arm, open-label, dose escalation, PK expansion and efficacy expansion study of phase I. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jiangsu HengRui Medicine Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface is being studied. Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms • Eligibility: Inclusion Criteria: * Signed and dated, written informed consent form (ICF) (ICF1 for B7-H6 testing for all patients except those with advanced or metastatic colorectal cancer (CRC); and…. Goal: This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has the B7-H6 marker or if they have colorectal cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Boehringer Ingelheim.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Brightline-2 trial tests whether brigimadlin (BI 907828) helps adults with advanced cancer of the biliary tract, pancreas, lung, or bladder. It’s for people whose cancer has not responded to standard treatment or for whom no standard treatment exists. Brigimadlin is taken as a tablet every 3 weeks, with regular visits to monitor tumor size and safety. Eligibility requires specific tumor biology (MDM2 amplification or TP53 wild-type) confirmed by tissue testing and measurable disease with good performance status. Key exclusions include prior brigimadlin or other MDM2/MDMX-p53 drugs, risk of significant bleeding, or conditions that could make participation unsafe. The study is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether people with advanced solid tumors who have stable disease can stop PD-1/PD-L1 treatment after one year without harming outcomes. It is for patients being treated with PD-1/PD-L1 drugs (like pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab). Participants are randomly assigned to stop treatment after about one year or continue treatment until the cancer progresses, to learn the best length of therapy. To join, patients must have at least stable disease on scans within six weeks of randomization; those with progressive disease before randomization or immune-related toxicity that prevents staying on therapy beyond one year are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers is being studied. Conditions: Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver, Metastatic Carcinoma in the Lung +2 • Eligibility: Inclusion Criteria: * Patients must have histological confirmation of solid metastatic cancer with at least one metastatic or primary lesion in the liver or lung/chest, except for group…. Goal: This phase I/II trial studies the side effects and best dose of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody BMS-986156 (BMS-986156) when given together with ipilimumab and nivolumab with or without stereotactic body radiation therapy and to see how well they work in treating patients with lung/chest or liver cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as BMS-986156, ipilimumab, and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests ZW25 (zanidatamab) added to standard first-line chemotherapy in people with HER2-expressing gastrointestinal cancers that are unresectable or metastatic, specifically gastroesophageal adenocarcinoma, biliary tract cancer, or colorectal cancer. The study has two parts: Part 1 checks safety and tolerability and helps establish a recommended dose for the combination, and Part 2 evaluates the anti-tumor activity. Eligible participants have HER2-expressing tumors, are unresectable or metastatic, and have good performance status with adequate organ and heart function; colorectal cancer participants must have wild-type RAS/BRAF, with additional biomarker criteria by part. Key exclusions include prior HER2-targeted therapy, recent systemic cancer treatment (with limited exceptions), untreated brain metastases, significant cardiac disease, QTc prolongation, active infections, or uncontrolled HIV/HBV/HCV.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tested whether tumor tissue and blood can identify biomarkers that predict how advanced biliary tract cancer responds to a chemotherapy combination of gemcitabine, cisplatin, and nab-paclitaxel. It enrolled adults with biliary tract cancer that is unresectable, metastatic, or recurrent, who planned to receive the triplet chemotherapy after tumor sequencing. Researchers used biopsy samples for in-house sequencing and collected blood over time to study cell-free DNA and circulating tumor cells and their relation to response and progression. Eligibility required measurable disease and good performance status, with key exclusions including uncontrolled illness, prior palliative chemotherapy for BTC, and dementia or other conditions affecting consent. Status: COMPLETED; Sponsor: CHA University; Phase: Unknown.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Treatment Strategy for Adult Congenital Biliary Dilation is being studied. Conditions: Congenital Biliary Dilation • Eligibility: Inclusion Criteria ： 1. Age: Adults (≥18 years). 2. Study population: Consecutive patients treated at Beijing Tsinghua Changgung Hospital. 3. Time frame: Underwent surgical treatment between November 2014…. Goal: The management of congenital biliary dilations (CBDs), including choledochal cysts, represents one of the most challenging areas in hepatobiliary surgery due to their potential implications for long-term morbidity and malignant transformation. While CBDs have a relatively low incidence in Western populations (1/150,000-1/100,000), the prevalence is notably higher in Asian countries (1/1,000), making it a significant global health concern. Phase/Status/Sponsor: Unknown phase; COMPLETED; Beijing Tsinghua Chang Gung Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer is being studied. Conditions: Undernutrition, Gastrointestinal Cancer • Eligibility: Case group selection criteria: Inclusion Criteria: * 18 years ≤ Age ≤ 80 years * Colorectal pancreatic cancer * Undernutrition related to cancer (weight loss \> 5% weight…. Goal: Undernutrition associated with cancer, or cancer cachexia results from a deterioration of the energy balance that leads to a gradual mobilization of energy reserves in the body and to increasing deterioration of the nutritional status of patients. This will thus significantly reduce quality of life and survival of patients with a lower tolerance to cancer treatments. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital, Tours.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients is being studied. Conditions: Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma +14 • Eligibility: Inclusion Criteria: \- Exclusion Criteria: \-. Goal: AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Phase/Status/Sponsor: Unknown phase; AVAILABLE; AVM Biotechnology Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The Liver and Biliary Tumor Tissue Registry collects tissue from adults having surgery to remove a liver or biliary mass or from those having a biopsy, to store for future research. - A blood sample may also be collected at enrollment. - The goal is to support translational research on the biology, causes, and prognosis of liver and biliary diseases, including studies that may use patient-derived xenografts. - Eligibility: people scheduled for surgical resection of a liver or biliary mass; Exclusions: under 18 years old or prior radiation to the mass. - Status: terminated.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a non-interventional registry study in France to collect data on the use of TheraSphere for liver cancers. It includes people with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCC), or liver metastases from colon cancer who have received a reimbursed dose of TheraSphere. The study aims to learn how effective TheraSphere is in real-world practice, including safety, quality of life, and survival, and to support reimbursement claims in France. Eligibility requires consent to collect medical data and having received a reimbursed dose; exclusions are opposing data collection or not having received a reimbursed dose. Status: COMPLETED.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests immune therapies durvalumab and tremelimumab, with or without the chemotherapy capecitabine, as adjuvant treatment after curative surgery for biliary tract cancer. - It is for adults whose biliary tract cancer was completely resected with no metastasis, within 16 weeks of surgery, and who have good performance status. - The main goal is to see whether the treatment improves recurrence-free survival at 12 months, with secondary aims including overall survival, safety, quality of life, and biomarker analyses. - In a pilot phase, 40 patients are randomized 1:1 to receive durvalumab+tremelimumab with or without capecitabine to identify the more promising approach for potential testing against the current standard capecitabine; key exclusions include metastatic disease, active infection, prior immunotherapy, and autoimmune disorders.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study is being studied. Conditions: Biliary Tract Carcinoma • Eligibility: Inclusion Criteria * Has histologically confirmed diagnosis of advanced (metastatic) and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer) * Has measurable disease based…. Goal: In this China Extension study, pembrolizumab plus gemcitabine/cisplatin will be compared with placebo plus gemcitabine/cisplatin as first-line therapy in Chinese adults with advanced and/or unresectable biliary tract carcinoma. The primary hypothesis is pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to overall survival (OS). Phase/Status/Sponsor: Unknown phase; COMPLETED; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests RXC004 alone and in combination with pembrolizumab in adults whose advanced solid tumors progressed after standard therapy. - It has three parts: Module 1 treats RNF43 loss-of-function pancreatic cancer, Module 2 treats biliary tract cancer, and Module 3 tests RXC004 with pembrolizumab in BTC. - The goal is to learn early signs of benefit, using progression-free survival at 6 months for Modules 1 and 2 and objective response rate for Module 3, along with safety data. - Eligible participants must have measurable disease and adequate organ function; key exclusions include prior RXC004 exposure, brain metastases, active infections, pregnancy, and in Module 3, prior PD-1/PD-L1 therapy or pembrolizumab-related contraindications.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 is being studied. Conditions: Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma +8 • Eligibility: Inclusion Criteria: INT230-6 monotherapy Cohorts EC2 and EC3, combination with KEYTRUDA® cohort DEC2 and combination with Yervoy cohort FEC. Where criteria diverge the DEC2 and FEC specific criteria…. Goal: This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Phase/Status/Sponsor: Unknown phase; COMPLETED; Intensity Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers is being studied. Conditions: HER2-expressing Cancers • Eligibility: Inclusion Criteria: * Pathologically-confirmed diagnosis of breast cancer, gastroesophageal adenocarcinoma (GEA), or other HER2-expressing cancer with evidence of locally advanced (unresectable) and/or metastatic disease. * Dose-escalation (Cohort 1):…. Goal: This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; Zymeworks BC Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder is being studied. Conditions: Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder, Bile Duct Cancer +1 • Eligibility: Inclusion Criteria: 1. Patient has carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder. 2. Patient must have sufficient tumor tissue available for submission. 3.…. Goal: DKN-01 is a humanized monoclonal antibody (Mab) with neutralizing activity against Dkk-1 and is being developed as an anti-neoplastic agent. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of DKN-01 in combination with gemcitabine and cisplatin in patients with carcinoma primary to the intra- or exta-hepatic biliary system or gallbladder. Phase/Status/Sponsor: Unknown phase; COMPLETED; Leap Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.